A Phase III Randomized Double-Blind Clinical Trial of Pembrolizumab (MK-3475) plus Chemotherapy (XP or FP) versus Placebo plus Chemotherapy (XP or FP) as Neoadjuvant/Adjuvant Treatment for Subjects with Gastric ad Gastroesophageal Junction (GEJ) Adenocarcinoma (KEYNOTE-585)
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
